Kevin Tan - Jan 9, 2025 Form 4 Insider Report for Solid Biosciences Inc. (SLDB)

Role
CFO & Treasurer
Signature
/s/ David Tyronne Howton as attorney-in-fact for Kevin Tan
Stock symbol
SLDB
Transactions as of
Jan 9, 2025
Transactions value $
-$15,849
Form type
4
Date filed
1/13/2025, 06:51 PM
Previous filing
Feb 16, 2024
Next filing
Feb 11, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SLDB Common Stock Options Exercise +11.3K +63.88% 28.9K Jan 9, 2025 Direct F1, F2
transaction SLDB Common Stock Sale -$15.8K -4.07K -14.11% $3.89 24.8K Jan 10, 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SLDB Restricted Stock Units Options Exercise $0 -11.3K -33.33% $0.00 22.5K Jan 9, 2025 Common Stock 11.3K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units convert to common stock on a one-for-one basis.
F2 Includes 4,152 and 4,152 shares of common stock acquired under the Solid Biosciences Inc. Employee Stock Purchase Plan on May 31, 2024 and November 29, 2024, respectively.
F3 This sale was made to cover withholding taxes following the vesting of the previously granted restricted stock units. The sales do not represent a discretionary trade by Mr. Tan.
F4 The restricted stock units were granted on January 9, 2023 (the "Grant Date") and vest over four years, with 25% of the original number of shares vesting on each anniversary of the Grant Date until the fourth such anniversary.